Stock Performance - The company has 19.63 million restricted shares that will be unlocked for trading on December 10, 2025, which may increase market liquidity and potentially impact short-term stock price volatility [2] Project Progress - In August 2025, the company announced that the actual investment for two major IPO fundraising projects ("100 tons/year precious metal catalyst project" and "4100 tons/year high-end organic iodine and bromine new materials project") amounted to 141 million yuan, a decrease of nearly 100 million yuan from the planned investment of 241 million yuan. The company also proposed to use no more than 250 million yuan of idle raised funds and 500 million yuan of its own funds to purchase financial products, which has attracted market attention [3] Regulatory Situation - Data from the third-party environmental platform "Green Network" indicates that in the first quarter of 2025, the company's incinerator exhaust outlet recorded exceedances of carbon monoxide and nitrogen oxides. However, the company claimed in its 2025 semi-annual report that it achieved compliant emissions, raising concerns about the authenticity of its information disclosure [4]

Group 1 - The core point of the article is that Boyuan Co., Ltd. (301617) reported a total of 9,584 shareholders as of February 13, 2026 [1]

Group 1 - The core viewpoint of the article is that Boyuan Co., Ltd. is capable of providing customized quality levels of lithium iodide for solid electrolytes based on varying downstream technological routes and application scenarios [2] Group 2 - The company engages with investors through an interactive platform, indicating a commitment to transparency and responsiveness to market inquiries [2] - The quality requirements for lithium iodide differ according to customer specifications, showcasing the company's flexibility in meeting diverse client needs [2]

| 8.公司人员、资产、财务、机构、业务等方面是否独立 √ | | | --- | --- | | 9.公司与控股股东及实际控制人是否不存在同业竞争 √ | | | 注 1：公司于 年 月 日召开 年第一次职工代表大会，选举于福强为公司第二届董事会职 2025 9 4 | 2025 | | 关于选举第二届董事会职工代表董事的公告 工代表董事，详情见公告编号：2025-046 | | | （二）内部控制 | | | 现场检查手段：（1）查阅内部审计部门资料，包括内部审计部门任职人员资料、内部 | | | 审计制度、内部审计部门出具的历次内部审计报告；（2）查阅审计委员会资料，包括 | | | 相关会议材料、会议纪要等；（3）查阅公司章程、对外投资管理制度以及投资决策相 | | | 关的董事会决议。 | | | 1.是否按照相关规定建立内部审计制度并设立内部审计部门 √ | | | （如适用） | | | 2.是否在股票上市后六个月内建立内部审计制度并设立内部 √ | | | 审计部门（如适用） | | | √ 3.内部审计部门和审计委员会的人员构成是否合规（如适用） | | | 4.审计委员会是否至少每季度召开 ...

中泰证券股份有限公司 关于山东博苑医药化学股份有限公司 2025 年度持续督导培训情况的报告 深圳证券交易所： 中泰证券股份有限公司（以下简称"中泰证券"、"保荐人"）根据《深圳证券 交易所上市公司自律监管指引第 13 号——保荐业务》《证券发行上市保荐业务管 理办法》等相关规定对山东博苑医药化学股份有限公司（以下简称"博苑股份"、 "公司"）进行了 2025 年度持续督导培训，报告如下： 一、本次持续督导培训的基本情况 （一）保荐人：中泰证券股份有限公司 （二）保荐代表人：尹广杰、林宏金 二、本次培训内容 保荐人通过现场会议+视频会议的方式对上述培训对象进行了培训，培训内 容主要为上市公司监管法规体系、董事与高管的权利与义务、董事会秘书的责任 与义务、股份减持与短线交易、信息披露及针对性介绍上市公司违规案例等，重 点对深圳证券交易所规范运作中的重大事项管理进行了培训（包括募集资金管理、 对外担保、财务资助、关联交易、短线交易、董事高管履职等）。保荐人对《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规进行了介绍，并结合违规案例对 相关法 ...

Group 1 - On February 9, Boyuan Co., Ltd. saw a stock increase of 1.82% with a trading volume of 133 million yuan, while the margin trading data indicated a net margin buy of -1.39 million yuan for the day [1] - As of February 9, the total margin trading balance for Boyuan Co., Ltd. was 181 million yuan, which accounted for 4.42% of its circulating market value, indicating a high level compared to the 90th percentile over the past year [1] - The company had no short selling activity on February 9, with a short selling balance of 0 shares, also reflecting a high level compared to the 90th percentile over the past year [1] Group 2 - Boyuan Co., Ltd. was established on August 6, 2008, and is located in Shouguang City, Shandong Province, focusing on the research, production, and sales of fine chemicals, including organic and inorganic iodides, precious metal catalysts, and luminescent materials [2] - The company's main business revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2] - For the period from January to September 2025, Boyuan Co., Ltd. achieved an operating income of 1.073 billion yuan, representing a year-on-year growth of 6.60%, while the net profit attributable to shareholders decreased by 22.53% to 132 million yuan [2] Group 3 - Since its A-share listing, Boyuan Co., Ltd. has distributed a total of 88.41 million yuan in dividends [3] - As of September 30, 2025, the top ten circulating shareholders included several new institutional investors, with notable holdings such as 1.3456 million shares by Zhonghang New Start Flexible Allocation Mixed A [3]

Group 1 - The company, Boyuan Co., Ltd. (301617), reported that as of January 30, 2026, the total number of shareholders is 9,117 [1]

Core Viewpoint - The investment by Boyuan Co., Ltd. in Shandong Hongdian New Materials Co., Ltd. is a strategic decision aimed at expanding its business in the semiconductor materials sector, leveraging the growing market potential in this industry [1] Company Overview - Shandong Hongdian New Materials Co., Ltd. specializes in core carbon-based materials for the electronic semiconductor industry, focusing on the research, production, and sales of porous graphite, isostatic graphite, and high-purity carbon powder [1] - The core product, porous graphite, is essential for silicon carbide crystal growth and has achieved domestic import substitution, supplying leading domestic silicon carbide companies in bulk [1] Investment Rationale - The investment is based on the broad market prospects of the semiconductor industry and aligns with the company's development strategy [1] - The investment amount is relatively small, and the shareholding ratio is low, indicating minimal short-term impact on the company's financial status [1]

Group 1 - The company announced a change in the signing registered accountants for the 2025 audit project from Wu Hui and Geng Xin to Wu Hui and Qi Tieqiao [2] - The quality reviewer for the project is Wang Weiqiu [2]

证券代码：301617 证券简称：博苑股份 公告编号：2026-001 关于变更签字注册会计师的公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 山东博苑医药化学股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开的第二届董事会第九次会议和第二届监事会第七次会议，于 2025 年 5 月 15 日召开了 2024 年年度股东会，上述会议审议通过了《关于续聘 2025 年度会 计师事务所的议案》。同意续聘天健会计师事务所（特殊普通合伙）（以下简称 "天健所"）为公司 2025 年度的财务报告及内部控制审计机构。具体内容详见 公司于 2025 年 4 月 25 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于续聘 2025 年度会计师事务所的公告》（公告编号：2025-021）。 近日，公司收到天健所出具的《关于变更签字注册会计师的函》，现将具体 情况公告如下： 一、签字注册会计师变更情况 天健所作为公司 2025 年度的财务报告及内部控制审计机构，原指派吴慧女 士（项目合伙人）、耿欣女士为签字注册会计师，鉴于原签字注册会计师耿 ...